Indications for imatinib mesylate therapy and clinical management

Oncologist

Volumn 9, Issue 3, 2004, Pages 271-281

  Guilhot, François ^a,b  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b University of Poitiers   (France)

Author keywords

Chronic myeloid leukemia, therapy; Imatinib; Protein tyrosine kinase

Indexed keywords

ALANINE AMINOTRANSFERASE; ALLOPURINOL; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BCR ABL PROTEIN; BILIRUBIN; CALCIUM; COAL TAR; COTRIMOXAZOLE; CYTARABINE; DIURETIC AGENT; GLUCOCORTICOID; IMATINIB; INTERFERON; LIVER ENZYME; MAGNESIUM; ONDANSETRON; PROCHLORPERAZINE; PROTEIN TYROSINE KINASE INHIBITOR;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; BRAIN EDEMA; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; CONTINUING EDUCATION; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DYSPEPSIA; DYSPNEA; EDEMA; FACE EDEMA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; HEADACHE; HEART TAMPONADE; HUMAN; HYPOKALEMIA; LICHENOID; LIVER TOXICITY; LUNG EDEMA; MAJOR CLINICAL STUDY; MUSCLE CRAMP; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; ONCOLOGY; PITYRIASIS ROSEA; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; RIGOR; SIDE EFFECT; SORE THROAT; STEVENS JOHNSON SYNDROME; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC AGENTS; BONE MARROW; DRUG ERUPTIONS; EDEMA; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LIVER DISEASES; MUSCLE CRAMP; PIPERAZINES; PYRIMIDINES;

EID: 2942619994     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-3-271     Document Type: Review

References (59)

1. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002;346:683-693.
2. Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1084-1086.
3. Buchdunger E, Zimmermann J, Mett H et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100-104.
4. Buchdunger E, Cioffi CL, Law N et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-145.
5. Rubin BP, Singer S, Tsao C et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-8121.
6. Krystal GW. Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents. Drug Resist Update 2001;4:16-21.
7. Hughes T, Kaeda J, Branford S et al. Molecular responses to imatinib (STI571) or interferon + Ara-C as initial therapy for CML: results in the IRIS study. Blood 2002;100:93a-94a.
8. Cortes J, Giles F, O'Brien S et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 2003;102:83-86.
9. Kantarjian HM, Talpaz M, O'Brien S et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003;101:473-475.
10. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
11. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042.
12. Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652.
13. Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-1937.
14. Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-3539.
15. Stone RM. Optimizing treatment of chronic myeloid leukemia: a rational approach. The Oncologist 2004;9:259-270.
16. Peggs K, Mackinnon S. Imatinib mesylate - the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003;348:1048-1050.
17. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
18. Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol 2003;40(suppl 2):21-25.
19. van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-1423.
20. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
21. Apperley JF, Gardembas M, Melo JV et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2003;347:481-487.
22. Rubin BP, Schuetze SM, Eary JF et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002;20:3586-3591.
23. Cortes J, Ault P, Koller C et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 2003;101:4714-4716.
24. Gleich GJ, Leiferman KM, Pardanani A et al. Treatment of hypereosinophilic syndrome with imatinib mesylate. Lancet 2002;359:1577-1578.
25. Gotlib J, Malone JM, DeAngelo DJ et al. Imatinib mesylate (GLEEVEC) induces rapid and complete hematologic remissions in patients with idiopathic hypereosinophilic syndrome (HES) without evidence of BCR-ABL or activating mutations in c-KIT and platelet-derived growth factor receptor-beta (PDGFR-beta). Blood 2002;100:798a.
26. Nolasco I, Carvalho S, Parreira A et al. Rapid and complete response to imatinib mesylate (STI571) in a patient with idiopathic hypereosinophilia. Blood 2002;100:346b-347b.
27. Pardanani A, Reeder T, Porrata LF et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003;101:3391-3397.
28. Cools J, DeAngelo DJ, Gotlib J et al. A tyrosine kinase created by fusion of the PDGFRA and F1P1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-1214.
29. Schaller JL, Burkland GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed 2001;3:1-5.
30. Cohen MH, Williams G, Johnson JR et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002;8:935-942.
31. Deininger MW, O'Brien SG, Ford JM et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637-1647.
32. Reckmann AH, Fischer T, Peng B et al. Effect of food on STI571 (Glivec) pharmacokinetics and bioavailability. Proc Am Soc Clin Oncol 2001;20:307a.
33. Esmaeli B, Prieto VG, Butler CE et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer 2002;95:881-887.
34. Ramar K, Potti A, Mehdi SA. Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia. J Clin Oncol 2003;21:172-173.
35. Druker BJ, Sawyers CL, Capdeville R et al. Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program);2001:87-112.
36. Briasoulis E, Pavlidis N. Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. The Oncologist 2001;6:153-161.
37. Ebnöether M, Stentoft J, Ford J et al. Cerebral oedema as a possible complication of treatment with imatinib. Lancet 2002;359:1751-1752.
38. Barton JC, Jones SC, Lamberth WC et al. Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia. Am J Hematol 2002;71:139-140.
39. Freedberg IM, Eisen AZ, Wolff K et al. Fitzpatrick's Dermatology in General Medicine, Fifth Edition. New York: McGraw Hill, 1999.
40. Brouard MC, Prins C, Mach-Pascual S et al. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia. Dermatology 2001;203:57-59.
41. McCabe MJ Jr, Santini RP, Rosenspire AJ. Low and nontoxic levels of ionic mercury interfere with the regulation of cell growth in the WEHI-231 B-cell lymphoma. Scand J Immunol 1999;50:233-241.
42. Kanbe T, Soma Y, Kawa Y et al. Serum levels of soluble stem cell factor and soluble KIT are elevated in patients with atopic dermatitis and correlate with the disease severity. Br J Dermatol 2001;144:1148-1153.
43. Raanani P, Goldman JM, Ben-Bassat I. Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571. J Clin Oncol 2002;20:869-870.
44. Etienne G, Cony-Makhoul P, Mahon FX. Imatinib mesylate and gray hair. N Engl J Med 2002;347:446.
45. Valeyrie L, Bastuji-Garin S, Revuz J et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003;48:201-206.
46. Schwarz M, Kreuzer KA, Baskaynak G et al. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol 2002;69:254-256.
47. Hsiao LT, Chung HM, Lin JT et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol 2002;117:620-622.
48. Vidal D, Puig L, Sureda A et al. STI571-induced Stevens-Johnson syndrome. Br J Haematol 2002;119:274-275.
49. Konstantopoulos K, Papadogianni A, Dimopoulou M et al. Pityriasis rosea associated with imatinib (STI571, Gleevec). Dermatology 2002;205:172-173.
50. Lim DS, Muir J. Oral lichenoid reaction to imatinib (STI571, Gleevec). Dermatology 2002;205:169-171.
51. Miyagawa S, Fujimoto H, Ko S et al. Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour. Br J Dermatol 2002;147:406-407.
52. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-1285.
53. Roujeau JC. Treatment of severe drug eruptions. J Dermatol 1999;26:718-722.
54. Rule SA, O'Brien SG, Crossman LC. Managing cutaneous reactions to imatinib therapy. Blood 2002;100:3434-3435.
55. Bauer S, Hagen V, Pielken HJ et al. Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function. Anticancer Drugs 2002;13:847-849.
56. Ohyashiki K, Kuriyama Y, Nakajima A et al. Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia 2002;16:2160-2161.
57. Remick SC, Ramanathan RK, Mulkerin D et al. P-5340: a phase 1 pharmacokinetic study of STI-571 in patients (pts) with advanced malignancies and varying degrees of renal dysfunction. Proc Am Soc Clin Oncol 2003;22:126.
58. Sneed TB, Kantarjian HM, Talpaz M et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 2004;100:116-121.
59. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.